Open an Account
search icon
2
NOTIFICATIONS
Best Algo trading app in India
Bigul

PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Change in Directorate

 This is in continuation to our earlier letter dated December 11, 2019 intimating, inter-alia, about appointment of Mr. Shantanu Yeshwant Nalavadi on the Board of Directors of the Company as an Additional Director. We would like to further update that he has been appointed as a Nominee Director for and on behalf of Vistra ITCL (India) Limited, the Debenture Trustee, pursuant to the Debenture Trust Deed dated April 06, 2019. You are requested to take the above information on record.
11-12-2019
Bigul

PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Change in Directorate

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that: a. Mr. Shantanu Yeshwant Nalavadi has been appointed as an Additional Director of the Company (in the capacity of Non-Executive Director) with effect from December 10, 2019. He is not related to any Director of the Company. Brief profile of Mr. Shantanu Yeshwant Nalavadi is enclosed herewith as Annexure - A. In accordance with the circular dated June 20, 2018, issued by the Stock Exchanges, we have got the confirmation from Mr. Shantanu Yeshwant Nalavadi that he is not debarred from accessing the capital market and / or restrained from holding the office of Director by virtue of any SEBI Order or any other such authority. b. Mr. Nithin Krishna Kaimal, Non-Executive Director of the Company, has resigned from the directorship of the Company with effect from December 10, 2019. You are requested to take the above information on record.
11-12-2019
Bigul

PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Panacea Biotec Ltd. is pleased to announce the launch of ViLACT, available in four formulations (ViLACT, ViLACT M500, ViLACT M850 and ViLACT M1000), for treatment of Uncontrolled Type 2 Diabetes Mellitus patients. A copy of the Press Release being issued to the media, etc. in this regard is enclosed for your kind reference and record please.
10-12-2019
Bigul

PANACEA BIOTEC LTD. - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 This is with reference to CDSL''s Operating Instructions for Issuers/RTAs, which states that the Issuer/RTA shall inform the details of the securities dematerialized to all the Stock Exchanges where the securities are listed. Accordingly, we are enclosing herewith the data of shares dematerialized during the month of November, 2019
04-12-2019
Bigul

Panacea Biotec Ltd - 531349 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Dear Sir, Panacea Biotec Ltd. (PBL), one of India's leading Pharmaceutical and Biotechnology Company, as part of its organizational restructuring program has announced the following key managerial appointments/elevation in its top-level leadership: 1. Appointment of Mr. Susheel Umesh as Chief Executive - Domestic Formulations; 2. Elevation of Dr. Rajeeva Kumar Mangalum as Chief Operating Officer for the Pharmaceutical Operations; 3. Elevation of Mr. Dinesh Singla as Senior Vice President- Pharma Research & Pharma Regulatory Affairs. A copy of the Press Release being issued to the media, etc. in this regard is enclosed for your kind reference and record please. Kindly acknowledge the receipt.
19-11-2019
Bigul

PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Dear Sir, Panacea Biotec Ltd. (PBL), one of India's leading Pharmaceutical and Biotechnology Company, as part of its organizational restructuring program has announced the following key managerial appointments/elevation in its top-level leadership: 1. Appointment of Mr. Susheel Umesh as Chief Executive - Domestic Formulations; 2. Elevation of Dr. Rajeeva Kumar Mangalum as Chief Operating Officer for the Pharmaceutical Operations; 3. Elevation of Mr. Dinesh Singla as Senior Vice President- Pharma Research & Pharma Regulatory Affairs. A copy of the Press Release being issued to the media, etc. in this regard is enclosed for your kind reference and record please. Kindly acknowledge the receipt.
19-11-2019
Bigul

Panacea Biotec Ltd - 531349 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 In continuation to our letter dated November 14, 2019 for approving the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and half year ended September 30, 2019 and pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith newspaper copies of Extract of Statement of aforesaid Unaudited Financial Results, published in the following newspapers on November 15, 2019:- Business Standard (English); Desh Sewak (Punjabi)
15-11-2019
Bigul

PANACEA BIOTEC LTD. - 531349 - Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half Year Ended September 30, 2019

 In continuation to our letter dated November 05, 2019 and pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we would like to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. November 14, 2019, inter-alia, considered and approved the Standalone and Consolidated Unaudited Financial Results (Provisional) of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter and half year ended September 30, 2019. The same were also reviewed by the Audit Committee in its meeting held earlier on November 14, 2019. A copy of the same along with the Limited Review Report is enclosed herewith as Annexure - A. The meeting of the Board of Directors commenced at 02:30 P.M. and concluded at 5:45 P.M. We request you to kindly bring the above information to the notice of your members.
14-11-2019
Bigul

Panacea Biotec Ltd - 531349 - Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half Year Ended September 30, 2019

 In continuation to our letter dated November 05, 2019 and pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we would like to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. November 14, 2019, inter-alia, considered and approved the Standalone and Consolidated Unaudited Financial Results (Provisional) of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter and half year ended September 30, 2019. The same were also reviewed by the Audit Committee in its meeting held earlier on November 14, 2019. A copy of the same along with the Limited Review Report is enclosed herewith as Annexure - A. The meeting of the Board of Directors commenced at 02:30 P.M. and concluded at 5:45 P.M. We request you to kindly bring the above information to the notice of your members.
14-11-2019
Bigul

Panacea Biotec Ltd - 531349 - Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half Year Ended September 30, 2019

 In continuation to our letter dated November 05, 2019 and pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we would like to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. November 14, 2019, inter-alia, considered and approved the Standalone and Consolidated Unaudited Financial Results (Provisional) of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter and half year ended September 30, 2019. The same were also reviewed by the Audit Committee in its meeting held earlier on November 14, 2019. A copy of the same along with the Limited Review Report is enclosed herewith as Annexure - A. The meeting of the Board of Directors commenced at 02:30 P.M. and concluded at 5:45 P.M. We request you to kindly bring the above information to the notice of your members.
14-11-2019
Next Page
Close

Let's Open Free Demat Account